WP
OCUL icon

Woodline Partners’s Ocular Therapeutix OCUL Stock Holding History

Woodline Partners’s Portfolio OCUL Stock Details OCUL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$16.4M Hold
1,667,609
– – 0.05% 411
2026
Q1 		$14.1M Buy
1,667,609
+1,473
+0.1% +$14K 0.05% 428
2025
Q4 		$20.2M Buy
1,666,136
+49
+0% +$595 0.08% 311
2025
Q3 		$19.5M Buy
1,666,087
+915,137
+122% +$10.9M 0.09% 292
2025
Q2 		$6.97M Hold
750,950
– – 0.04% 502
2025
Q1 		$5.5M Sell
750,950
-251,485
-25% -$1.93M 0.04% 483
2024
Q4 		$8.56M Buy
1,002,435
+2,435
+0.2% +$23.8K 0.06% 381
2024
Q3 		$8.7M Buy
+1,000,000
New +$8.24M 0.07% 323

Other funds holding OCUL

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
SR
Summer Road West Palm Beach, Florida $161M AUM 27.24% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Woodline Partners's OCUL Position: Q2 2026 in Review

Woodline Partners held its Ocular Therapeutix (OCUL) position steady in Q2 2026 at 1,667,609 shares worth $16.4M. The position accounts for 0.05% of the portfolio, ranked #411.

Woodline Partners first reported a position in OCUL in Q3 2024 and has held it in 8 quarters since. The position peaked at $20.2M in Q4 2025. 263 funds tracked by Wall St. Rank hold OCUL as of Q2 2026.

  • Woodline Partners held 1,667,609 shares of Ocular Therapeutix worth $16.4M as of Q2 2026.
  • Woodline Partners left its Ocular Therapeutix share count unchanged in Q2 2026.
  • Ocular Therapeutix made up 0.05% of Woodline Partners's portfolio in Q2 2026, its #411 holding.
  • Woodline Partners first reported a position in Ocular Therapeutix in Q3 2024 and has held it in 8 quarters since.
  • Woodline Partners's Ocular Therapeutix position peaked at $20.2M in Q4 2025.
  • 263 funds tracked by Wall St. Rank held Ocular Therapeutix as of Q2 2026.

Based on Woodline Partners's 13F filing for Q2 2026, filed 14 Aug 2026.